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In serum, most thyroxine (T4) and triiodothyronine (T3) is
bound to binding proteins, and only 0.02% of T4 and 0.3%
of T3 are free (FT4 and FT3) (1–4). It is generally accepted
that only free hormones in circulation are metabolically
active. Chemiluminescence enzyme immunoassays are
among the most frequently used in routine clinical labora-
tories for the determination of FT4 and FT3.
We undertook this study to compare the performance of
two analyzers for FT3 and FT4 determination, the former
‘‘Vitros Eci/Eciq’’ and the new ‘‘Vitros3600’’, both from
Ortho-Clinical Diagnostics (Rochester, NY, USA). In both
methods a direct, competitive immunoassay technique that
employs a horseradish peroxidase (HRP)-labeled antibody
conjugate and a ligand on the well surface is used. The
bound HRP conjugate is measured by a luminescent reaction,
and the signal is inversely related to the concentrations of
FT4 or FT3 in serum. Both methods use the same reagent
pack and the same set of calibrators. They both feature
Microwell with enhanced chemiluminescence properties
and Intellicheck Technology that verifies analytical per-
formance and reduces potential errors by providing real-time
operator notification and tracking. In addition, Vitros3600
features Microsensor Technology that automatically per-
forms sample quality indice checks: hemolysis, icterus and
turbidity can be quantified without additional reagents or
sample volume, with no impact on turn around time (TAT)
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and costs. This capability reduces the time, labor and error
potential of manual interpretation. With the Vitros3600, the
use of a disposable tip, in addition to dispensing the sample,
has been extended to the dispensing of reagents: this elimi-
nates any possible contamination of reagent/reagent, and also
drastically decreases the use of wash solution and the pro-
duction of waste liquid, because it is no longer required a
washing protocol of fixed probes before and after contact
with a reagent. The opportunity for loading and unloading
of reagents with the routine in progress has also been intro-
duced, and wash and waste liquids can be changed ‘on the
fly’. Up to 80 samples (q10 in emergency) can be loaded
in the Vitros3600 as compared to 60 samples in the Vitros
Eci/Eciq. The high productivity of the Vitros3600 (about
twice that of Vitros Eci/Eciq) is obtained also by an increase
in the size of the incubator, by doubling the number of
microwell washing probes (two instead of one), by increas-
ing the capacity of reagent supplies (31 positions instead of
20) and by integrated packages of luminolq
enhancer (three instead of two).
Comparison studies were performed using samples
obtained from 329 subjects (Total) grouped as follows: 118
euthyroid blood donors (Eu), 57 obese patients without thy-
roid diseases and free of medications affecting thyroid func-
tion (Ob), 54 hypothyroid (thyroidectomized) patients free of
levo-thyroxine therapy before radioiodine treatment for thy-
roid cancer (Hypo), 57 hyperthyroid patients free of anti-
thyroid medications, the day before administration of
131-iodine (Hyper), 21 patients with cardiac disease (CD),
22 uremic patients before hemodialysis (Ur 1). Samples from
uremic patients were also obtained 4 h after hemodialysis
(Ur 2). Assay imprecision was determined by analyzing a
serum pool with 10 replicates in each run (intrassay) and in
10 different runs (interassay). The within-run imprecision
values obtained with the Vitros3600 were 1.9% (FT3) and
1.0% (FT4), while they were 3.7% (FT3) and 2.1% (FT4)
with the former Eci/Eciq. The between-run imprecision val-
ues were 5.3% (FT3) and 4.0% (FT4) with the Vitros3600,
4.1% (FT3) and 4.0% (FT4) with Eci/Eciq.
The values of FT3 and FT4 and the results of statistical
analysis in various groups are reported in Tables 1 and 2.
Close agreement between the two methods for measurement
of both hormones was demonstrated. The slight differences
observed in some patient’s subgroups, mainly in the case of
FT3 measurements, may not be attributed to a better per-
formance of one assay over the other, and from a clinical
point of view, they do not affect interpretation of the results.
Furthermore, both methods have a similar ability to detect
changes in thyroid hormone balance. Low FT3 concentra-
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Table 1 Results of FT4 and FT3 assays by Vitros Eci/Eciq and Vitros3600.
FT4 Vitros Eci/Eciq FT4 Vitros3600 FT3 Vitros Eci/Eciq FT3 Vitros3600
Eu
Mean"SD 10.0"1.6 10.4"1.6 3.8"0.4 3.8"0.5a (1)
Median and IQR 10.0 (7.9 to 11.9)b 10.2 (7.9 to 12.6)b 3.8 (3.3 to 4.3)b 3.8 (3.1 to 4.4)b
Ob
Mean"SD 10.0"1.8 10.5"1.9 3.9"0.4 3.4"0.5c (1)
Hypo
Mean"SD 0.3"0.7 0.3"0.6 1.1"0.5 0.9"0.4d (1)
Hyper
Mean"SD 14.1"7.1 13.8"6.4 5.2"2.9 4.8"2.6
CD
Mean"SD 12.9"3.0 12.2"2.7a (2) 2.9"0.4 2.9"0.4
Ur 1
Mean"SD 12.5"3.0 12.3"3.1 3.0"0.7 2.8"0.4a (3)
Median and IQR 11.5 (9.2 to 15.6) 11.4 (9.9 to 15.2) 2.9 (2.8 to 3.3) 2.8 (2.5 to 3.0)e
Ur 2
Mean"SD 21.0"9.5 17.3"5.7 3.6"1.3 3.1"0.8
Median and IQR 17.7 (14.1 to 27.2)f 16.2 (13.4 to 21.5)e,f 3.2 (2.6 to 4.2)f 3.1 (2.6 to 3.5)e,f
Total
Mean"SD 9.5"5.6 9.7"5.4 3.5"1.8 3.3"1.7c (2)
Data are presented as mean"SD (pg/mL). For uremic patients and euthyroid controls, data are also presented as median and IQR. The
Passing-Bablok non-parametric test (5) vs. Vitros Eci/Eciq (reference method) for FT4 and FT3 was used. A significant proportional bias
(slope b) indicates that the disagreement between the two assays is concentration-dependent, while a significant constant bias (intercept a)
means a systematic difference along the entire range of concentrations: c(a) different from 0; a(a) different from 0 and (b) different from
1; d(b) different from 1. Wilcoxon test for paired samples, ep-0.01 vs. Vitros Eci/Eciq. Kruskal-Wallis Test, fp-0.05 vs. pre-hemodialysis;
bp-0.05 vs. Ur 1 and Ur 2 (post-hoc comparisons using the Bonferroni correction of significance were conducted when necessary).
a(1): as–0.62, 95% CI: –1.26 to –0.12; bs1.16, 95% CI: 1.04 to 1.33; a(2): as1.63, 95% CI: 0.4 to 2.9; bs0.91, 95% CI: 0.8 to 0.9;
a(3): as0.57, 95% CI: 0.2 to 1.1; bs0.74, 95% CI: 0.56 to 0.87; c(1): as–0.99, 95% CI: –2.21 to –0.17; c(2): as–0.20, 95% CI: –0.28
to –0.12; d(1): bs0.81, 95% CI: 0.71 to 0.90.
Table 2 The relationship between FT4 and FT3 concentrations
measured with the Vitros Eci/Eciq and Vitros3600 was tested using
Pearson’s correlation or Spearman’s rank correlation in case of non-
Gaussian distribution of measurements.
Vitros Eci/Eciq Vitros3600
Eu 0.547a 0.541a
Ob 0.06 0.098
Hypo 0.630a 0.696a
Hyper 0.897a 0.882a
CD 0.222 0.207
Ur 1 0.301 –0.123
Total 0.835a 0.834a
A significant correlation was found in the total population and in
the subgroups of unselected patients with normal thyroid profile,
hypothyroid and hyperthyroid patients (ap-0.01). There were no
significant differences between the correlation coefficient values
obtained by Vitros Eci/Eciq or Vitros3600 in these groups. Isolated
T3 thyrotoxicosis was not observed in the hyper group.
tions were found in uremic patients with no relevant differ-
ences between the two methods. Chronic kidney disease may
cause an alteration in serum thyroid hormone concentrations
in the absence of underlying intrinsic thyroid disorders. This
non-thyroidal illness syndrome is mainly characterized by a
decrease in total and unbound T3 concentrations due to
impaired conversion of T4 to T3 via peripheral deiodination
(6–8). The results of our study, indicating low FT3 concen-
trations in uremic patients, are in agreement with most
reports in the literature, with no relevant differences between
the two methods. After hemodialysis, an increase in FT4
values above the range of euthyroid subjects was observed.
This artifactual increase was the same regardless of the
equipment used, and could be explained by changes in serum
proteins or fatty acids, the appearance of circulating inhibi-
tors of plasma T4 binding activity, heparin administration
and/or reduction of extracellular fluid volume after haemo-
dialysis (9, 10). This increase was smaller for the Vitros3600
than for the Vitros Eci/Eciq. Yet, we conclude that FT4
measurement by both methods is affected too severely to be
useful for routine work in this specific clinical setting.
In conclusion, the results of our study indicate that: 1)
from a clinical point of view, FT3 and FT4 measurements
by the Vitros3600 are comparable to those obtained by the
former Vitros Eci/Eciq, with an increase in productivity and
no impact on turnaround time or costs; 2) a manufacturer,
using the same immunochemical reagents and the same tech-
nical components, may provide the same results for a given
assay using two different analyzers; 3) the similarity in the
results is strengthened by the observation that the same arti-
facts are observed in both cases.
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